Efficacy of tocilizumab in adult H syndrome: a promising therapeutic option

Int J Dermatol. 2021 Oct;60(10):e417-e419. doi: 10.1111/ijd.15649. Epub 2021 May 5.

Authors

Pierre Hamann¹, Philippe Moguelet², François Chasset³, Jeremie Delaleu³, Annick Barbaud³, Patricia Senet³, Camille Frances³, Tullia De Risi-Pugliese³

Affiliations

¹ Service de Dermatologie, Institut Gustave Roussy, Université Paris-Saclay, Paris, France.
² Service d'anatomo-pathologie, Hôpital Tenon, AP-HP, Faculté de Médecine, Sorbonne Université, Paris, France.
³ Service de Dermatologie et Allergologie, Hôpital Tenon, AP-HP, Sorbonne Université, Paris, France.

PMID: 33951194
DOI: 10.1111/ijd.15649

No abstract available

Publication types

Letter

MeSH terms

Adult
Antibodies, Monoclonal, Humanized
Contracture*
Histiocytosis*
Humans
Interleukin-6
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Interleukin-6
tocilizumab